» Articles » PMID: 36103112

Astragaloside IV Regulates Insulin Resistance and Inflammatory Response of Adipocytes Via Modulating CTRP3 and PI3K/AKT Signaling

Overview
Journal Diabetes Ther
Date 2022 Sep 14
PMID 36103112
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Emerging evidence showed that adipocytes are important regulators in controlling insulin resistance in type 2 diabetes mellitus (T2DM). So far, compounds isolated from natural plants have been widely studied for their roles in alleviating T2DM-associated complications. This work evaluated the actions of astragaloside IV (AS-IV) on insulin resistance and inflammatory biomarker expression in adipocytes and explored the potential mechanisms.

Methods: Glucose consumption of the adipocytes was determined by a glucose assay kit; the mRNA expression levels of glucose transporter type 4 (GLUT-4), interleukin-6 (IL-6), TNF-α and C1q tumor necrosis factor-related protein 3 (CTRP3) were measured by quantitative real-time PCR (qRT-PCR); the protein levels were determined by western blot assay and enzyme-linked immunosorbent assay.

Results: AS-IV concentration-dependently increased glucose consumption in the insulin resistance adipocytes. Further qRT-PCR results showed that AS-IV concentration-dependently reduced adipocyte IL-6 and TNF-α expression. Moreover, GLUT-4 expression in adipocytes was also significantly upregulated by AS-IV. Furthermore, we found that AS-IV concentration-dependently increased CTRP3 expression in adipocytes. CTRP3 silence decreased glucose consumption, upregulated IL-6 and TNF-α expression and downregulated GLUT-4 mRNA expression in 200 µM AS-IV-treated adipocytes. Moreover, AS-IV treatment enhanced the activity of phosphoinositide 3-kinase (PI3K)/AKT signaling in adipocytes, which was markedly attenuated by CTRP3 silencing. Importantly, inhibition of PI3K/AKT signaling also attenuated AS-IV induced an increase in glucose consumption and GLUT-4 expression and a decrease in IL-6 and TNF-α expression of adipocytes.

Conclusions: Collectively, our data indicated that AS-IV attenuated insulin resistance and inflammation in adipocytes via targeting CTRP3/PI3K/Akt signaling.

Citing Articles

The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective.

Li X, Wang F, Chen M, Ling L, Zhao F, Peng D BMC Womens Health. 2024; 24(1):366.

PMID: 38909214 PMC: 11193179. DOI: 10.1186/s12905-024-03218-5.


Metabolites of traditional Chinese medicine targeting PI3K/AKT signaling pathway for hypoglycemic effect in type 2 diabetes.

Feng Y, Ren Y, Zhang X, Yang S, Jiao Q, Li Q Front Pharmacol. 2024; 15:1373711.

PMID: 38799166 PMC: 11116707. DOI: 10.3389/fphar.2024.1373711.


Exploring the mechanism of Jinlida granules against type 2 diabetes mellitus by an integrative pharmacology strategy.

Gu H, Zhong L, Zhang Y, Sun J, Liu L, Liu Z Sci Rep. 2024; 14(1):10286.

PMID: 38704482 PMC: 11069553. DOI: 10.1038/s41598-024-61011-8.


CTRP3 alleviates mitochondrial dysfunction and oxidative stress injury in pathological cardiac hypertrophy by activating UPRmt via the SIRT1/ATF5 axis.

Shi L, Tan Y, Zheng W, Cao G, Zhou H, Li P Cell Death Discov. 2024; 10(1):53.

PMID: 38278820 PMC: 10817931. DOI: 10.1038/s41420-024-01813-x.


Could Cyclosiversioside F Serve as a Dietary Supplement to Prevent Obesity and Relevant Disorders?.

Qin S, Chen J, Zhong K, Li D, Peng C Int J Mol Sci. 2023; 24(18).

PMID: 37762063 PMC: 10531328. DOI: 10.3390/ijms241813762.

References
1.
Shimizu T, Saito T, Aoki-Saito H, Okada S, Ikeda H, Nakakura T . Resolvin E3 ameliorates high-fat diet-induced insulin resistance via the phosphatidylinositol-3-kinase/Akt signaling pathway in adipocytes. FASEB J. 2022; 36(3):e22188. DOI: 10.1096/fj.202100053R. View

2.
Gui D, Huang J, Guo Y, Chen J, Chen Y, Xiao W . Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression. Cytokine. 2013; 61(3):970-7. DOI: 10.1016/j.cyto.2013.01.008. View

3.
Yan Z, Zhao J, Gan L, Zhang Y, Guo R, Cao X . CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner. PLoS One. 2017; 12(6):e0178253. PMC: 5478095. DOI: 10.1371/journal.pone.0178253. View

4.
Moradi N, Najafi M, Sharma T, Fallah S, Koushki M, Peterson J . Circulating levels of CTRP3 in patients with type 2 diabetes mellitus compared to controls: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2020; 169:108453. DOI: 10.1016/j.diabres.2020.108453. View

5.
Zhang J, Wu C, Gao L, Du G, Qin X . Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Adv Pharmacol. 2020; 87:89-112. DOI: 10.1016/bs.apha.2019.08.002. View